A Phase 4 interventional study of Therapeutic plasma exchange (TPE) and Standard of care in COVID-19, sponsored by Emory University. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-21.
Sponsored by Emory University · Phase 4, Interventional, and Treatment
Many patients with Coronavirus Disease 2019 (COVID-19) have atypical blood clots. These blood clots can occur in either veins or arteries and be large, like in stroke or heart attack, or very tiny, called microthrombi. Some patients with COVID-19 even have blood clots despite being on anti-clotting medications. Blood with increased viscosity does not flow through the body normally, in the same way that syrup, a highly viscous liquid, and water, a minimally viscous liquid, flow differently. The researchers believe that hyperviscosity may contribute to blood clots and organ damage seen in patients with severe COVID-19. Plasma exchange removes a patient's plasma, which contains the large sticky factors that the researchers believe are increasing viscosity, and replaces it with plasma from healthy donors. In addition to providing important information about plasma exchange as a treatment in COVID-19 for patients, this study will provide data to justify resource and staffing decisions.
This study will enroll 20 participants who are critically ill from COVID-19. Participants will be randomized to receive therapeutic plasma exchange (TPE) or standard of care (SOC).
Critically ill COVID-19 patients have high rates of complications, including respiratory failure, renal impairment, and a coagulopathic state that may exacerbate these conditions and contribute to additional end organ injury. Consistent with a fundamentally distinct nature of COVID-19-associated disease, our preliminary studies demonstrate that patients with COVID-19 exhibit an increase in plasma viscosity. Furthermore, the researchers have found that plasma viscosity strongly correlates with sequential organ failure assessment (SOFA) scores, a mortality prediction score used in the intensive care unit (ICU), in COVID-19 infected patients. These results strongly suggest that altered blood flow secondary to hyperviscosity may contribute to end organ injury and therefore morbidity and mortality in the most critically ill COVID-19 patients. More detailed analysis of the potential etiology of COVID-19-associated plasma hyperviscosity has demonstrated that these patients also have significantly elevated levels of the plasma protein fibrinogen. Increased fibrinogen levels, which may be either entirely responsible for or at least contribute to hyperviscosity in these patients, may be the primary mediator of refractory hypercoagulability in this patient population. Thus, hyperviscosity induced by hyperfibrinogenemia may be a critical driver of morbidity and mortality in patients with COVID-19.
Therapeutic plasma exchange (TPE) is the only procedure known to directly and rapidly decrease plasma viscosity, suggesting that TPE may improve patient outcomes in critically ill patients with COVID-19 by decreasing plasma viscosity and thereby enhancing blood flow. However, as a procedure, extensive implementation of TPE would require significant devotion of hospital resources, including apheresis machines and the staff needed to successfully conduct these procedures. The procedures alone require staff to have prolonged interactions with critically ill COVID-19 patients, placing them at a potentially increased risk for contracting COVID-19. It is therefore essential that clear and unequivocal data be generated in order to accurately assess the risk and benefits of this procedure for both patients and staff. Such data will also aid in determining the necessary resources that may be needed to successfully conduct TPE for this patient population.
Participants will be randomized in a 1:1 ratio to receive TPE or SOC. Participants in the TPE study arm will receive two treatments of TPE with frozen plasma on sequential days. Plasma viscosity will be measured before TPE (Day 1) and following the second TPE treatment (Day 3 or 4). Participants in the SOC study arm will also have their plasma viscosity assessed on Days 1 and 3. Participants will be followed for the duration of their hospital stay.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 20 is below the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Emory University is the lead sponsor of 1,386 studies on the registry; 236 are open to participants now.
Of its 229 completed or terminated interventional studies of FDA-regulated products, 174 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Evidence of COVID-19 infection documented by a laboratory test either by one of the following:
Exclusion Criteria:
Participants with COVID-19-associated hyperviscosity randomized to receive therapeutic plasma exchange (TPE).
Biological: Therapeutic plasma exchange (TPE)
Participants with COVID-19-associated hyperviscosity randomized to receive standard of care treatment.
Other: Standard of care
Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
Plasma Viscosity
Plasma viscosity is measured in centipoise (cP). The normal range is 1.4 - 1.8 cP and measurements above this range indicate increased viscosity.
Time frame: Day 1 (within 24 hours prior to TPE), Day 4 (within 24 hours of last TPE)
Cumulative Incidence of Adverse Events
The primary safety endpoint is assessed as the cumulative incidence of adverse events directly associated with TPE during the study period as determined by clinical judgment of ICU team providing direct patient care and the study PI.
Time frame: Up to Day 28
Cumulative All Cause Mortality
The number of participants dying from any cause is reported as a cumulative measures of mortality.
Time frame: Up to Day 28
Cumulative Count of Bleeding and Thromboembolic Complications
The number of bleeding and thromboembolic complications will be compared between study arms. This endpoint is a composite outcome including any acute bleeding requiring transfusion support, venous thrombosis (deep vein thrombosis or pulmonary embolism), arterial clots (myocardial infarction, stroke, limb ischemia), renal replacement therapy or catheter line related clots. The values reported are cumulative.
Time frame: Up to Day 28
Time to Treatment Failure
Time to treatment failure will be assessed in days and is defined as plasma viscosity \> 3.5 cP and/or the participant is offered TPE outside of trial by primary clinical team.
Time frame: Up to Day 28
Duration of ICU Stay
The number of days spent in the ICU after study enrollment is presented here. All patients are included in calculating the reported mean, including those whose ICU stay ended due to death.
Time frame: Up to Day 48
Duration of Hospital Stay
The number of days spent hospitalized after study enrollment is presented here. All patients are included in calculating the reported mean, including those whose hospitalization ended due to death.
Time frame: Up to Day 48
Discharge Disposition
The number of participants in each study arm discharged to home or to a long-term acute care (LTAC) hospital, versus palliative care or death.
Time frame: Up to Day 48
Clinical Status Score
The clinical status of participants was assessed using a single item modified from the World Health Organization (WHO) ordinal clinical severity scale for COVID. The instrument was customized for this study to evaluate thrombotic/bleeding events. In this 12-point ordinal scale, a score of 1 indicates no evidence of infection and the severity of the clinical status increases as the number of necessary interventions increases to the final score of 12, which is death. All patients were included at every timepoint recorded, with "terminal" scores carried over from the measure before for those that expired or fully recovered.
Time frame: Day 1 (day of study enrollment), Day 4 (one day after second TPE treatment), Days 7, 14, 21, and 28
Body Temperature
Body temperature will be assessed in degrees Celsius.
Time frame: Days 7, 14, 21, and 28
Systolic Blood Pressure
Systolic blood pressure will be assessed in millimeters of mercury (mm Hg).
Time frame: Days 7, 14, 21, and 28
Diastolic Blood Pressure
Diastolic blood pressure will be assessed in millimeters of mercury (mm Hg).
Time frame: Days 7, 14, 21, and 28
Heart Rate
Heart rate will be assessed as beats per minute.
Time frame: Days 7, 14, 21, and 28
Respiratory Rate
Respiratory rate will be assessed as breaths per minute.
Time frame: Days 7, 14, 21, and 28
Ventilator Days
The number of days participants are on a ventilator, among participants who were ever on a ventilator after study enrollment.
Time frame: Up to Day 28
Ventilator Oxygen Percent (FiO2)
The oxygen percent delivered with a ventilator that is needed to maintain blood oxygen levels will be compared between study arms.
Time frame: Days 7, 14, 21, and 28
Positive End-Expiratory Pressure (PEEP)
PEEP during ventilator use is measured in centimeters of water (cmH2O) and is the pressure in the lungs above atmospheric pressure, at the end of an exhalation. Higher PEEP (10 cmH2O or greater) may be associated with improved mortality, compared with PEEP below 10 cmH2O.
Time frame: Day 1 (day of study enrollment), Day 4 (one day after second TPE treatment), Days 7, 14, 21, and 28
Vasopressor Requirements
Whether or not breathing assistance from vasopressors is needed will be compared between study arms.
Time frame: Days 7, 14, 21, and 28
Need for Treatment From a Registered Respiratory Therapist (RRT)
Whether or not breathing assistance from an RRT is needed will be compared between study arms.
Time frame: Days 7, 14, 21, and 28
Sequential Organ Failure Assessment (SOFA) Score
The Sequential Organ Failure Assessment (SOFA) score is a method of predicting mortality that is based on the degree of dysfunction of six organ systems (respiratory, nervous, cardiovascular, liver, coagulation, and kidneys). Each organ system is scored between 0 and 4, where 0 indicates normal function and 4 indicates a high degree of dysfunction. Total scores range from 0 to 24. A score of 0-6 is associated with a mortality rate of less than 10% while a score between 16 and 24 is associated with a greater than 90% mortality rate.
Time frame: Day 1 (day of study enrollment), Day 4 (one day after second TPE treatment), Days 7, 14, 21, and 28
Partial Pressure of Arterial Oxygen (PaO2)/Percentage of Inspired Oxygen (FiO2) Ratio
The PaO2/FiO2 ratio is decreased with hypoxia. A value of less than 200 indicates acute respiratory distress syndrome (ARDS).
Time frame: Day 1 (day of study enrollment), Day 4 (one day after second TPE treatment), Days 7, 14, 21, and 28
Ventilatory Ratio
Ventilatory ratio will be documented. The formula for the ventilatory is \[minute ventilation (ml/min) × PaCO2 (mm Hg)\]/(predicted body weight × 100 × 37.5).
Time frame: Days 7, 14, 21, and 28
White Blood Count (WBC)
The normal range for WBC is 3,400 to 6,600 cells per microliter (cells/mL) of blood. A high WBC occurs when inflammation or infection is present.
Time frame: Days 7, 14, 21, and 28
Hemoglobin (Hb)
Hemoglobin is measured in grams per deciliter (grams/dL). A normal Hb count for males is 13.2 to 16.6 grams/dL and a normal count for females is 11.6 to 15 grams/dL. A patient has anemia when their hemoglobin is low.
Time frame: Days 7, 14, 21, and 28
Hematocrit (Hct)
A measure of hematocrit is the volume of red blood cells in the total blood volume. Normal hematocrit for males is 40 to 54% and a normal measurement for females is 36 to 48%
Time frame: Days 7, 14, 21, and 28
Platelet Count
A normal platelet is 150,000 to 450,000 platelets per microliter of blood. An excess of platelets in the blood can be caused by inflammation or infection.
Time frame: Days 7, 14, 21, and 28
Mean Platelet Volume (MVP)
MVP is a measurement of platelet size. Platelet size tends to be increased when platelet count is high. Typical platelet volume is 9.4 to 12.3 femtoliters (fL).
Time frame: Days 7, 14, 21, and 28
Blood Urea Nitrogen (BUN)
The normal range for BUN is 7 to 20 milligrams per deciliter (mg/dL) of blood. A high BUN value indicates that kidneys are not functioning well.
Time frame: Days 7, 14, 21, and 28
Creatinine
The normal range for creatinine is 0.84 to 1.21 mg/dL of blood. High serum creatinine indicates that kidneys are not functioning well.
Time frame: Day 1 (day of study enrollment), Day 4 (one day after second TPE treatment), Days 7, 14, 21, and 28
Bilirubin
For adults, normal values for total bilirubin are around 1.2 mg/dL of blood. High bilirubin indicates that the liver is not functioning well.
Time frame: Days 7, 14, 21, and 28
Total Protein
The normal range for total protein is 6.0 to 8.3 g/dL of blood. High levels of total protein can occur with inflammation or infection while low levels may indicate kidney or liver problems, or malnutrition.
Time frame: Days 7, 14, 21, and 28
Albumin
The normal range for albumin is 3.4 to 5.4 g/dL of blood. High albumin may indicate acute infection while low albumin can indicate malnutrition or liver disease.
Time frame: Days 7, 14, 21, and 28
C-reactive Protein (CRP)
A normal value for CRP (with a standard test) is less than 10 milligrams per liter (mg/L) of blood. CRP increases with inflammation, which could be attributed to an infection, chronic inflammatory disease or heart disease.
Time frame: Day 1 (day of study enrollment), Day 4 (one day after second TPE treatment), Days 7, 14, 21, and 28
Interleukin 6 (IL-6)
A normal value for IL-6 is 1.8 picograms per milliliter (pg/mL) or less. IL-6 is increased in patients with infections or chronic inflammation.
Time frame: Days 7, 14, 21, and 28
Prothrombin Time (PT)
Prothrombin time is a measurement of the time it takes (in seconds) for blood to clot. A normal value is 10 to 14 seconds.
Time frame: Days 7, 14, 21, and 28
International Normalized Ratio (INR)
An INR of around 1.1 is considered normal. Lower INR can means that blood is clotting faster than desired while higher INR indicates that blood is clotting slower than normal.
Time frame: Days 7, 14, 21, and 28
Activated Partial Thromboplastin Time (aPTT)
The aPTT test is a measurement of blood clotting time. Normal values for aPTT are around 30 to 40 seconds. Higher aPTT values can indicate a bleeding risk.
Time frame: Days 7, 14, 21, and 28
Anti-factor Xa (Anti-Xa)
The anti-factor Xa assay measures plasma heparin and is useful with monitoring anticoagulation therapy. Interpretation of the resulting values depends on the anticoagulation medication used as well as the dosing schedule and indication. Patients not taking heparin should have an anti-Xa value of 0 units per milliliter (U/mL).
Time frame: Days 7, 14, 21, and 28
Fibrinogen
Fibrinogen is a protein that helps with the formation of blood clots. For adults, the normal range of fibrinogen is 200 to 400 mg/dL. Fibrinogen can be increased in patients with liver, kidney, or inflammatory diseases. The risk of developing a thromboembolism is increased with chronically high levels of fibrinogen.
Time frame: Day 1 (day of study enrollment), Day 4 (one day after second TPE treatment), Days 7, 14, 21, and 28
D-dimer
The D-dimer blood test is a method of screening for deep vein thrombosis or pulmonary embolism. A normal D-dimer value is less than 0.50 micrograms per milliliter (mcg/mL) of blood. High levels of D-dimer can occur when a patient has a major blood clot, infection, or liver disease.
Time frame: Day 1 (day of study enrollment), Day 4 (one day after second TPE treatment), Days 7, 14, 21, and 28
Participants were recruited from Emory University Hospital, Emory University Hospital Midtown, and Emory Saint Joseph's Hospital in Atlanta, Georgia, USA. Participant enrollment began July 17, 2020 and all follow-up assessments were completed by March 18, 2021.
| Milestone | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Plasma viscosity is measured in centipoise (cP). The normal range is 1.4 - 1.8 cP and measurements above this range indicate increased viscosity.
| cP | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Baseline | 2.35 ± 0.37 | 2.47 ± 0.34 |
| Post-treatment | 1.61 ± 0.09 | 2.47 ± 0.48 |
The primary safety endpoint is assessed as the cumulative incidence of adverse events directly associated with TPE during the study period as determined by clinical judgment of ICU team providing direct patient care and the study PI.
| adverse events | Therapeutic Plasma Exchange (TPE) |
|---|---|
| Cumulative Incidence of Adverse Events | 1 |
The number of participants dying from any cause is reported as a cumulative measures of mortality.
| Participants | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 to Day 3 | 0 | 0 |
| Day 1 to Day 7 | 0 | 0 |
| Day 1 to Day 14 | 0 | 2 |
| Day 1 to Day 21 | 1 | 4 |
| Day 1 to Day 28 | 2 | 5 |
The number of bleeding and thromboembolic complications will be compared between study arms. This endpoint is a composite outcome including any acute bleeding requiring transfusion support, venous thrombosis (deep vein thrombosis or pulmonary embolism), arterial clots (myocardial infarction, stroke, limb ischemia), renal replacement therapy or catheter line related clots. The values reported are cumulative.
| Participants | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 to Day 3 | 0 | 0 |
| Day 1 to Day 7 | 1 | 0 |
| Day 1 to Day 14 | 1 | 0 |
| Day 1 to Day 21 | 2 | 2 |
| Day 1 to Day 28 | 2 | 2 |
Time to treatment failure will be assessed in days and is defined as plasma viscosity \> 3.5 cP and/or the participant is offered TPE outside of trial by primary clinical team.
| days | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Time to Treatment Failure | 5.5 ± 2.12 | 2.5 ± 3.54 |
The number of days spent in the ICU after study enrollment is presented here. All patients are included in calculating the reported mean, including those whose ICU stay ended due to death.
| days | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Duration of ICU Stay | 23.1 ± 15.7 | 16.0 ± 11.4 |
The number of days spent hospitalized after study enrollment is presented here. All patients are included in calculating the reported mean, including those whose hospitalization ended due to death.
| days | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Duration of Hospital Stay | 27.2 ± 12.4 | 21.7 ± 12.0 |
The number of participants in each study arm discharged to home or to a long-term acute care (LTAC) hospital, versus palliative care or death.
| Participants | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Home or LTAC | 7 | 5 |
| Palliative care or death | 3 | 5 |
The clinical status of participants was assessed using a single item modified from the World Health Organization (WHO) ordinal clinical severity scale for COVID. The instrument was customized for this study to evaluate thrombotic/bleeding events. In this 12-point ordinal scale, a score of 1 indicates no evidence of infection and the severity of the clinical status increases as the number of necessary interventions increases to the final score of 12, which is death. All patients were included at every timepoint recorded, with "terminal" scores carried over from the measure before for those that expired or fully recovered.
| score on a scale | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 (day of study enrollment) | 7.0 (6.0 to 7.75) | 8.0 (7.25 to 8.0) |
| Day 4 (1 day after second TPE treatment) | 7.0 (6.0 to 7.0) | 8.0 (7.25 to 8.0) |
| Day 7 | 7.0 (6.0 to 8.0) | 8.0 (7.0 to 8.0) |
| Day 14 | 8.0 (6.0 to 8.0) | 7.5 (7.0 to 9.75) |
| Day 21 | 7.5 (5.5 to 8.0) | 8.0 (7.0 to 12.0) |
| Day 28 | 7.0 (5.5 to 8.75) | 10.0 (7.0 to 12.0) |
Body temperature will be assessed in degrees Celsius.
No measurements were reported for this outcome.
Systolic blood pressure will be assessed in millimeters of mercury (mm Hg).
No measurements were reported for this outcome.
Diastolic blood pressure will be assessed in millimeters of mercury (mm Hg).
No measurements were reported for this outcome.
Heart rate will be assessed as beats per minute.
No measurements were reported for this outcome.
Respiratory rate will be assessed as breaths per minute.
No measurements were reported for this outcome.
The number of days participants are on a ventilator, among participants who were ever on a ventilator after study enrollment.
| days | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Ventilator Days | 22.6 ± 11.6 | 19.2 ± 11.2 |
The oxygen percent delivered with a ventilator that is needed to maintain blood oxygen levels will be compared between study arms.
No measurements were reported for this outcome.
PEEP during ventilator use is measured in centimeters of water (cmH2O) and is the pressure in the lungs above atmospheric pressure, at the end of an exhalation. Higher PEEP (10 cmH2O or greater) may be associated with improved mortality, compared with PEEP below 10 cmH2O.
| cmH2O | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 (day of study enrollment) | 12.7 ± 5.0 | 15.9 ± 5.9 |
| Day 4 (one day after second TPE treatment) | 11.6 ± 4.3 | 13.0 ± 3.7 |
| Day 7 | 13.0 ± 6.2 | 11.3 ± 3.9 |
| Day 14 | 13.0 ± 2.0 | 13.3 ± 2.7 |
| Day 21 | 11.0 ± 1.2 | 11.0 ± 2.0 |
| Day 28 | 11.0 ± 2.6 | 12.7 ± 7.0 |
Whether or not breathing assistance from vasopressors is needed will be compared between study arms.
No measurements were reported for this outcome.
Whether or not breathing assistance from an RRT is needed will be compared between study arms.
No measurements were reported for this outcome.
The Sequential Organ Failure Assessment (SOFA) score is a method of predicting mortality that is based on the degree of dysfunction of six organ systems (respiratory, nervous, cardiovascular, liver, coagulation, and kidneys). Each organ system is scored between 0 and 4, where 0 indicates normal function and 4 indicates a high degree of dysfunction. Total scores range from 0 to 24. A score of 0-6 is associated with a mortality rate of less than 10% while a score between 16 and 24 is associated with a greater than 90% mortality rate.
| score on a scale | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 (day of study enrollment) | 10.5 (8.5 to 12.75) | 13.0 (11.25 to 14.0) |
| Day 4 (one day after second TPE treatment) | 11.0 (7.75 to 12.5) | 11.5 (11.0 to 12.75) |
| Day 7 | 11.0 (10.0 to 12.0) | 12.0 (11.25 to 13.75) |
| Day 14 | 12.5 (8.75 to 13.75) | 12.5 (11.0 to 15.0) |
| Day 21 | 11.5 (8.75 to 12.0) | 13.0 (10.75 to 15.75) |
| Day 28 | 11.5 (8.25 to 12.75) | 12.0 (9.0 to 15.75) |
The PaO2/FiO2 ratio is decreased with hypoxia. A value of less than 200 indicates acute respiratory distress syndrome (ARDS).
| PaO2/FiO2 ratio | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 (day of study enrollment) | 219 ± 102 | 166 ± 79 |
| Day 4 (one day after second TPE treatment) | 132 ± 80 | 157 ± 44 |
| Day 7 | 151 ± 131 | 141 ± 54 |
| Day 14 | 109 ± 21 | 101 ± 43 |
| Day 21 | 104 ± 32 | 145 ± 2 |
| Day 28 | 108 ± 54 | 146 ± 127 |
Ventilatory ratio will be documented. The formula for the ventilatory is \[minute ventilation (ml/min) × PaCO2 (mm Hg)\]/(predicted body weight × 100 × 37.5).
No measurements were reported for this outcome.
The normal range for WBC is 3,400 to 6,600 cells per microliter (cells/mL) of blood. A high WBC occurs when inflammation or infection is present.
No measurements were reported for this outcome.
Hemoglobin is measured in grams per deciliter (grams/dL). A normal Hb count for males is 13.2 to 16.6 grams/dL and a normal count for females is 11.6 to 15 grams/dL. A patient has anemia when their hemoglobin is low.
No measurements were reported for this outcome.
A measure of hematocrit is the volume of red blood cells in the total blood volume. Normal hematocrit for males is 40 to 54% and a normal measurement for females is 36 to 48%
No measurements were reported for this outcome.
A normal platelet is 150,000 to 450,000 platelets per microliter of blood. An excess of platelets in the blood can be caused by inflammation or infection.
No measurements were reported for this outcome.
MVP is a measurement of platelet size. Platelet size tends to be increased when platelet count is high. Typical platelet volume is 9.4 to 12.3 femtoliters (fL).
No measurements were reported for this outcome.
The normal range for BUN is 7 to 20 milligrams per deciliter (mg/dL) of blood. A high BUN value indicates that kidneys are not functioning well.
No measurements were reported for this outcome.
The normal range for creatinine is 0.84 to 1.21 mg/dL of blood. High serum creatinine indicates that kidneys are not functioning well.
| mg/dL | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 (day of study enrollment) | 2.5 ± 2.1 | 2.9 ± 1.8 |
| Day 4 (one day after second TPE treatment) | 2.0 ± 1.3 | 2.6 ± 1.7 |
| Day 1 | 2.3 ± 1.4 | 2.6 ± 1.7 |
| Day 14 | 2.6 ± 2.3 | 2.7 ± 1.8 |
| Day 21 | 2.3 ± 3.3 | 2.8 ± 1.7 |
| Day 28 | 1.3 ± 1.6 | 2.0 ± 1.6 |
For adults, normal values for total bilirubin are around 1.2 mg/dL of blood. High bilirubin indicates that the liver is not functioning well.
No measurements were reported for this outcome.
The normal range for total protein is 6.0 to 8.3 g/dL of blood. High levels of total protein can occur with inflammation or infection while low levels may indicate kidney or liver problems, or malnutrition.
No measurements were reported for this outcome.
The normal range for albumin is 3.4 to 5.4 g/dL of blood. High albumin may indicate acute infection while low albumin can indicate malnutrition or liver disease.
No measurements were reported for this outcome.
A normal value for CRP (with a standard test) is less than 10 milligrams per liter (mg/L) of blood. CRP increases with inflammation, which could be attributed to an infection, chronic inflammatory disease or heart disease.
| mg/L | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 (day of study enrollment) | 226 ± 74 | 234 ± 115 |
| Day 4 (one day after second TPE treatment) | 83 ± 37 | 179 ± 115 |
| Day 7 | 153 ± 153 | 210 ± 91 |
| Day 14 | 119 ± 94 | 195 ± 81 |
| Day 21 | 149 ± 134 | 71 ± 27 |
| Day 28 | 215 ± 213 | 141 ± 0 |
A normal value for IL-6 is 1.8 picograms per milliliter (pg/mL) or less. IL-6 is increased in patients with infections or chronic inflammation.
No measurements were reported for this outcome.
Prothrombin time is a measurement of the time it takes (in seconds) for blood to clot. A normal value is 10 to 14 seconds.
No measurements were reported for this outcome.
An INR of around 1.1 is considered normal. Lower INR can means that blood is clotting faster than desired while higher INR indicates that blood is clotting slower than normal.
No measurements were reported for this outcome.
The aPTT test is a measurement of blood clotting time. Normal values for aPTT are around 30 to 40 seconds. Higher aPTT values can indicate a bleeding risk.
No measurements were reported for this outcome.
The anti-factor Xa assay measures plasma heparin and is useful with monitoring anticoagulation therapy. Interpretation of the resulting values depends on the anticoagulation medication used as well as the dosing schedule and indication. Patients not taking heparin should have an anti-Xa value of 0 units per milliliter (U/mL).
No measurements were reported for this outcome.
Fibrinogen is a protein that helps with the formation of blood clots. For adults, the normal range of fibrinogen is 200 to 400 mg/dL. Fibrinogen can be increased in patients with liver, kidney, or inflammatory diseases. The risk of developing a thromboembolism is increased with chronically high levels of fibrinogen.
| mg/dL | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 (day of study enrollment) | 934 ± 79 | 860 ± 182 |
| Day 4 (one day after second TPE treatment) | 359 ± 71 | 807 ± 199 |
| Day 7 | 663 ± 166 | 806 ± 189 |
| Day 14 | 593 ± 143 | 762 ± 145 |
| Day 21 | 687 ± 125 | 598 ± 89 |
| Day 28 | 693 ± 33 | 116 ± 0 |
The D-dimer blood test is a method of screening for deep vein thrombosis or pulmonary embolism. A normal D-dimer value is less than 0.50 micrograms per milliliter (mcg/mL) of blood. High levels of D-dimer can occur when a patient has a major blood clot, infection, or liver disease.
| mcg/mL | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Day 1 (day of study enrollment) | 5187 ± 8973 | 1632 ± 1163 |
| Day 4 (one day after second TPE treatment) | 3519 ± 5575 | 6253 ± 9325 |
| Day 7 | 4041 ± 6408 | 1749 ± 1126 |
| Day 14 | 1819 ± 650 | 6767 ± 8304 |
| Day 21 | 6765 ± 13044 | 3136 ± 1911 |
| Day 28 | 16648 ± 28942 | 6567 ± 0 |
Collected over Information on TPE-associated adverse events was collected in patients receiving the study intervention (TPE) beginning with the initiation of the first TPE and continued up to 28 days after study enrollment. Adverse events were not collected for participants in the standard of care study arm.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Therapeutic Plasma Exchange (TPE) | 2/10 (20%) | 0/10 (0%) | 1/10 (10%) |
| Standard of Care | 5/10 (50%) | — | — |
| Event | Therapeutic Plasma Exchange (TPE) | Standard of Care |
|---|---|---|
| Mild tachycardiaCardiac disorders | 1/10 | — |
| Age, Continuous(years) | Therapeutic Plasma Exchange (TPE) | Standard of Care | Total |
|---|---|---|---|
| Mean | 58.9 ± 14.4 | 58.8 ± 9.04 | 58.9 ± 11.7 |
| Sex: Female, Male(Participants) | Therapeutic Plasma Exchange (TPE) | Standard of Care | Total |
|---|---|---|---|
| Female | 1 | 3 | 4 |
| Male | 9 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Therapeutic Plasma Exchange (TPE) | Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 5 | 7 | 12 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Race (NIH/OMB)(Participants) | Therapeutic Plasma Exchange (TPE) | Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 5 | 12 |
| White | 2 | 3 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(Participants) | Therapeutic Plasma Exchange (TPE) | Standard of Care | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Emory University